title: Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation.
authors.forename: B
authors.initials: B
authors.lastname: Sánchez-González
authors.forename: P
authors.initials: P
authors.lastname: Fernández-Abellán
authors.forename: M C
authors.initials: MC
authors.lastname: Garcia Garay
authors.forename: B
authors.initials: B
authors.lastname: Villarrubia
authors.forename: M F
authors.initials: MF
authors.lastname: Palmero
authors.forename: C
authors.initials: C
authors.lastname: Rivas
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016031:Liver Transplantation / Q000009:adverse effects*; D008223:Lymphoma / Q000209:etiology* / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D000069283:Rituximab; D033581:Stem Cell Transplantation / Q000379:methods*; D013997:Time Factors; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; D016572:Cyclosporine